Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients
NCT04140201
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Diabetic Retinopathy
Interventions
DRUG:
Simvastatin 40mg
DRUG:
Fenofibrate 200mg
DRUG:
Omega 3 fatty acid
Sponsor
Alaa Hassan ElBaz